查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1964019

自體免疫肝炎診斷和治療市場—全球產業規模、佔有率、趨勢、機會和預測：按類型、診斷方法、治療類型、地區和競爭對手分類，2021-2031年

Autoimmune Hepatitis Diagnosis And Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Diagnosis, By Treatment Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球自體免疫肝炎診斷和治療市場預計將從 2025 年的 125.6 億美元成長到 2031 年的 163.1 億美元，複合年成長率為 4.45%。

自體免疫肝炎 (AIH) 是一種慢性發炎性疾病，患者的免疫系統會攻擊肝細胞，因此需要進行準確的血清學鑑定和長期免疫抑制治療。市場成長的主要促進因素是全球自體免疫疾病盛行率的上升以及臨床意識的增強，這有利於早期發現和介入。此外，可靠的診斷生物標記的出現有助於將 AIH 與其他肝臟疾病區分開來。英國肝臟信託基金會 (英國 Liver Trust) 2024 年的一項患者調查顯示，16.7% 的肝病患者被確診為自體免疫肝炎，凸顯了該疾病帶來的沉重負擔。

市場概覽
預測期 2027-2031
市場規模：2025年 125.6億美元
市場規模：2031年 163.1億美元
複合年成長率：2026-2031年 4.45%
成長最快的細分市場 1型
最大的市場 北美洲

然而，診斷的複雜性和疾病誤診率高阻礙了市場擴張。自體免疫肝炎的症狀通常不明顯，或與其他肝臟疾病的症狀相似，導致診斷和治療啟動延遲。這種診斷上的不確定性，加上標準皮質類固醇療法帶來的嚴重副作用，常導致患者治療順從性低。這些因素使得制定維持市場成長所需的有效長期管理策略變得複雜。

市場促進因素

新型生物製藥和標靶免疫療法的出現，為傳統皮質類固醇療法提供了替代方案，從根本上改變了市場格局。這項轉變的驅動力在於產業結構大規模重組和旨在拓展自體免疫，旨在獲得用於治療系統性免疫疾病的先進小分子拮抗劑。這種強勁的投資環境正在加速推進針對肝臟自體免疫疾病的特定臨床計畫。尤其值得一提的是，2024年10月，Kether Life Sciences將研發重心轉向針對自體免疫肝炎的PORTOLA IIa期臨床試驗，並利用約1.48億美元的現金資金推動選擇性免疫蛋白酶體抑制劑的開發。

同時，非侵入性診斷影像和生物標記技術的進步正在解決疾病誤診和檢測延遲等長期存在的難題。識別準確的代謝特徵對於在不依賴侵入性切片檢查的情況下將自體免疫性肝炎與其他肝臟疾病區分開來至關重要。 2024年9月發表在《肝病學》（Hepatology）雜誌上的一項研究證實，一種由15種代謝物組成的新型代謝譜能夠以95%的靈敏度區分自體免疫肝炎與其他肝臟疾病。這些診斷技術的飛躍對於促進早期療育和確保患者獲得適當的標靶治療至關重要，並透過改善臨床管理推動市場成長。

市場挑戰

自體免疫肝炎 (AIH) 診斷的複雜性及其高誤診率是限制全球市場成長的重要阻礙因素。由於目前尚無針對該疾病的單一明確標記物，醫療服務提供者往往難以在不進行廣泛檢測的情況下將 AIH 與其他肝臟疾病（例如病毒性肝炎和代謝性肝病）區分開來。這種不確定性延長了診斷時間，延遲了必要的免疫抑制治療的啟動，並減少了疾病早期可治療階段的藥物用量。因此，有效藥物治療的窗口期往往被縮短，從而限制了製藥公司的商機。

這些診斷延遲的影響巨大，因為錯失早期診斷機會可能導致疾病不可逆的進展，並降低標準藥物治療方案的療效。根據美國肝病協會 (AASLD) 2024 年的數據，估計有 28% 至 33% 的自體免疫肝炎成年患者在首次臨床評估時已發展為肝硬化。如此高的晚期診斷率表明，相當一部分患者錯過了慢性病管理的早期階段，阻礙了治療市場的穩定成長。

市場趨勢

將人工智慧 (AI) 整合到診斷演算法中，透過解決組織學變異性問題，正在革新肝臟自體免疫的評估。利用深度學習模型自動識別切片檢查標本中的微觀特徵，我們實現了判讀的標準化，並減少了使診斷複雜化的觀察者間差異。此演算法的準確性在區分重疊的膽汁淤積性疾病方面尤其有效。例如，一項在 2024 年 6 月歐洲肝臟研究協會 (EASL) 年會上發表的研究表明，一種新型的基於 AI 的神經網路估計器能夠區分自體免疫肝炎和原發性膽汁性肝炎，其受試者工作特徵曲線下面積(AUROC) 達到了 0.81。這提高了診斷準確性並減少了誤診。

隨著診斷技術的進步，B細胞清除劑的廣泛應用正在重塑難治性疾病的治療策略。抗CD20單株抗體可直接針對參與致病性自體抗體產生的免疫細胞，目前正迅速應用於臨床實踐，用於治療對標準糖皮質激素無反應的患者。根據2024年5月發表於國際肝病研究學會官方期刊的一項註冊研究分析，接受利Rituximab治療的患者中有89%達到或維持了完全生化緩解。這種向標靶B細胞清除療法的轉變代表著治療策略的重大革新，確保了對傳統免疫抑制劑無反應的難治性患者群體的有效管理。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：自體免疫肝炎診斷與治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（類型 1、類型 2）
    • 診斷方法（血液檢查、切片檢查、影像檢查）
    • 治療方法（藥物治療、手術、肝臟移植、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美自體免疫肝炎診斷與治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲自體免疫肝炎診斷與治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區自體免疫肝炎診斷與治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲自體免疫肝炎診斷和治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲自體免疫肝炎診斷與治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球自體免疫肝炎診斷與治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie, Inc.
  • ADC Therapeutics SA
  • AstraZeneca PLC
  • Genentech, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Hiedelberg Pharma A/G
  • Takeda Pharmaceutical Company Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27598

The Global Autoimmune Hepatitis Diagnosis And Treatment Market is projected to expand from USD 12.56 Billion in 2025 to USD 16.31 Billion by 2031, reflecting a compound annual growth rate of 4.45%. Autoimmune Hepatitis (AIH), a chronic inflammatory condition where the immune system targets liver cells, necessitates accurate serological identification and long-term immunosuppressive therapy. The market's growth is primarily driven by the increasing global prevalence of autoimmune disorders and heightened clinical awareness, which supports earlier detection and intervention. Furthermore, the availability of reliable diagnostic biomarkers helps differentiate AIH from other liver conditions. Underscoring the disease's burden, a 2024 patient survey by the British Liver Trust indicated that 16.7% of respondents with a liver condition were diagnosed specifically with autoimmune hepatitis.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 12.56 Billion
Market Size 2031USD 16.31 Billion
CAGR 2026-20314.45%
Fastest Growing SegmentType 1
Largest MarketNorth America

However, market expansion is hindered by the complexity of diagnosis and the frequent misclassification of the disease. AIH often manifests with vague symptoms or mimics other liver pathologies, resulting in delays in diagnosis and the start of treatment. This ambiguity, coupled with the significant side effects linked to standard corticosteroid therapies, often leads to poor patient compliance. These factors complicate the effective long-term management strategies required to sustain continuous market growth.

Market Driver

The emergence of novel biologics and targeted immunotherapies is fundamentally transforming the market by providing alternatives to traditional corticosteroid treatments. This transition is bolstered by substantial industry consolidation and financial investments aimed at broadening autoimmune product lines. For instance, in May 2024, Incyte completed its $750 million acquisition of Escient Pharmaceuticals to obtain advanced small molecule antagonists for systemic immune disorders. This strong investment environment is accelerating specific clinical programs for liver autoimmunity; notably, Kezar Life Sciences shifted its focus in October 2024 to the PORTOLA Phase 2a clinical trial for autoimmune hepatitis, utilizing a cash balance of approximately $148 million to advance its selective immunoproteasome inhibitor.

Simultaneously, advancements in non-invasive diagnostic imaging and biomarker technologies are addressing historical issues related to disease misclassification and delayed detection. Identifying precise metabolic signatures is becoming essential for distinguishing this pathology from other liver conditions without relying solely on invasive biopsies. A study published in the journal Hepatology in September 2024 validated a new metabolic profile comprising 15 metabolites capable of differentiating autoimmune hepatitis from other hepatic diseases with 95% sensitivity. These diagnostic breakthroughs are crucial for facilitating early intervention and ensuring patients receive appropriate, targeted therapies, thereby driving market growth through enhanced clinical management.

Market Challenge

The intricate nature of diagnosing Autoimmune Hepatitis (AIH) and the high rate of misclassification act as significant restraints on global market growth. Because the disease does not present a single definitive marker, healthcare providers frequently struggle to distinguish AIH from other hepatic disorders, such as viral hepatitis or metabolic liver conditions, without conducting extensive testing. This uncertainty results in prolonged diagnostic timelines, which delays the administration of essential immunosuppressive therapies and lowers prescription volumes during the early, treatable stages of the disease. Consequently, the window for effective pharmacological intervention often narrows, limiting the revenue potential for drug manufacturers.

The consequences of these diagnostic delays are substantial, as missed early diagnoses allow the pathology to progress to irreversible stages where standard drug regimens are less effective. Data from the American Association for the Study of Liver Diseases in 2024 estimates that 28% to 33% of adults with Autoimmune Hepatitis already present with cirrhosis at the time of their initial clinical assessment. This high incidence of late-stage diagnosis suggests that a significant portion of the patient population is missing the primary phase of chronic disease management, thereby impeding the consistent expansion of the therapeutic market.

Market Trends

The incorporation of Artificial Intelligence into diagnostic algorithms is revolutionizing the assessment of liver autoimmunity by addressing histological variability. Deep learning models are being utilized to automate the recognition of microscopic features on biopsy slides, thereby standardizing interpretation and reducing the inter-observer variability that complicates diagnosis. This algorithmic precision is especially valuable for distinguishing the disease from overlapping cholestatic conditions. For example, a study presented at the European Association for the Study of the Liver (EASL) annual congress in June 2024 demonstrated that a new AI-based neural estimator distinguished autoimmune hepatitis from primary biliary cholangitis with an area under the receiver operating characteristic curve (AUROC) of 0.81, enhancing diagnostic accuracy and reducing misclassification.

Concurrent with diagnostic advancements, the increasing utilization of B-cell depleting agents is reshaping the management of refractory disease. Clinicians are rapidly adopting anti-CD20 monoclonal antibodies for patients who do not respond to standard corticosteroids, directly targeting the immune cells responsible for producing pathogenic autoantibodies. A registry analysis published in the official journal of the International Association for the Study of the Liver in May 2024 indicated that 89% of patients treated with Rituximab achieved or maintained a complete biochemical response. This shift toward targeted B-cell depletion marks a critical evolution in therapeutic strategies, ensuring effective management for difficult-to-treat patient cohorts where conventional immunosuppressants fail.

Key Market Players

  • AbbVie, Inc.
  • ADC Therapeutics SA
  • AstraZeneca PLC
  • Genentech, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Hiedelberg Pharma A/G
  • Takeda Pharmaceutical Company Limited

Report Scope

In this report, the Global Autoimmune Hepatitis Diagnosis And Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Autoimmune Hepatitis Diagnosis And Treatment Market, By Type

  • Type 1
  • Type 2

Autoimmune Hepatitis Diagnosis And Treatment Market, By Diagnosis

  • Blood Tests
  • Liver Biopsy
  • Imaging Tests

Autoimmune Hepatitis Diagnosis And Treatment Market, By Treatment Type

  • Medications
  • Surgery
  • Liver Transplant
  • Others

Autoimmune Hepatitis Diagnosis And Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Autoimmune Hepatitis Diagnosis And Treatment Market.

Available Customizations:

Global Autoimmune Hepatitis Diagnosis And Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Type 1, Type 2)
    • 5.2.2. By Diagnosis (Blood Tests, Liver Biopsy, Imaging Tests)
    • 5.2.3. By Treatment Type (Medications, Surgery, Liver Transplant, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Diagnosis
    • 6.2.3. By Treatment Type
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Diagnosis
        • 6.3.1.2.3. By Treatment Type
    • 6.3.2. Canada Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Diagnosis
        • 6.3.2.2.3. By Treatment Type
    • 6.3.3. Mexico Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Diagnosis
        • 6.3.3.2.3. By Treatment Type

7. Europe Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Diagnosis
    • 7.2.3. By Treatment Type
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Diagnosis
        • 7.3.1.2.3. By Treatment Type
    • 7.3.2. France Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Diagnosis
        • 7.3.2.2.3. By Treatment Type
    • 7.3.3. United Kingdom Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Diagnosis
        • 7.3.3.2.3. By Treatment Type
    • 7.3.4. Italy Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Diagnosis
        • 7.3.4.2.3. By Treatment Type
    • 7.3.5. Spain Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Diagnosis
        • 7.3.5.2.3. By Treatment Type

8. Asia Pacific Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Diagnosis
    • 8.2.3. By Treatment Type
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Diagnosis
        • 8.3.1.2.3. By Treatment Type
    • 8.3.2. India Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Diagnosis
        • 8.3.2.2.3. By Treatment Type
    • 8.3.3. Japan Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Diagnosis
        • 8.3.3.2.3. By Treatment Type
    • 8.3.4. South Korea Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Diagnosis
        • 8.3.4.2.3. By Treatment Type
    • 8.3.5. Australia Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Diagnosis
        • 8.3.5.2.3. By Treatment Type

9. Middle East & Africa Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Diagnosis
    • 9.2.3. By Treatment Type
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Diagnosis
        • 9.3.1.2.3. By Treatment Type
    • 9.3.2. UAE Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Diagnosis
        • 9.3.2.2.3. By Treatment Type
    • 9.3.3. South Africa Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Diagnosis
        • 9.3.3.2.3. By Treatment Type

10. South America Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Diagnosis
    • 10.2.3. By Treatment Type
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Diagnosis
        • 10.3.1.2.3. By Treatment Type
    • 10.3.2. Colombia Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Diagnosis
        • 10.3.2.2.3. By Treatment Type
    • 10.3.3. Argentina Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Diagnosis
        • 10.3.3.2.3. By Treatment Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Autoimmune Hepatitis Diagnosis And Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. ADC Therapeutics SA
  • 15.3. AstraZeneca PLC
  • 15.4. Genentech, Inc.
  • 15.5. Genmab A/S
  • 15.6. Gilead Sciences, Inc.
  • 15.7. GlaxoSmithKline PLC
  • 15.8. Pfizer, Inc.
  • 15.9. Hiedelberg Pharma A/G
  • 15.10. Takeda Pharmaceutical Company Limited

16. Strategic Recommendations

17. About Us & Disclaimer